Table 1.
Cohort characteristics.
| n = 107 | |
|---|---|
| Age at baseline, median [IQR] in years | 61 [54, 67] |
| Male sex, n (%) | 66 (61.7) |
| Time from transplantation to baseline, median [IQR] in years | 7 [4, 12] |
| Transplant type, n (%) | |
| Kidney | 50 (46.7) |
| Liver | 38 (35.5) |
| Lung | 19 (17.8) |
| Re-transplantation, n (%) | 19 (17.8) |
| Comorbidities, n (%) | |
| Diabetes mellitus | 24 (22.4) |
| Cardiovascular disease | 81 (75.7) |
| Dialysis | 2 (1.9) |
| Immunosuppressive maintenance therapy, n (%) | |
| Tacrolimus * | 72 (67.3) |
| Ciclosporin * | 23 (21.5) |
| mTOR inhibitor * | 17 (15.9) |
| Corticosteroids | 73 (68.2) |
| Antimetabolites | |
| None | 15 (14.0) |
| Azathioprine | 14 (13.1) |
| Mycophenolate | 78 (72.9) |
| Time from baseline to follow-up sample, median [IQR] in months | 4.5 [3.9, 4.9] |
| Time from baseline sample to vaccination, median [IQR] in days | 35 [21, 52] |
| Time from vaccination to follow-up, median [IQR] in days | 98 [80, 114] |
| Number of vaccine doses at baseline, n (%) | |
| 3 | 10 (9.3) |
| 4 | 92 (86.0) |
| 5 | 5 (4.7) |
| Type of latest COVID-19 vaccine at follow-up, n (%) | |
| Monovalent BNT162b2 | 5 (4.7) |
| Bivalent BNT162b2/BA.1 | 34 (31.8) |
| Bivalent BNT162b2/BA.4-5 | 68 (63.6) |
| Time between last two doses of COVID-19 vaccine, median [IQR] in days | 253 [241, 261] |
| Time between last two doses of COVID-19 vaccine, n (%) | |
| More than six months | 96 (89.7) |
| Less than six months | 11 (10.3) |
| Time of latest SARS-CoV-2 infection, n (%) | |
| Never infected | 30 (28.0) |
| Before baseline | 60 (56.1) |
| During follow-up | 17 (15.9) |
| Monoclonal anti-SARS-CoV-2 antibody within six months before baseline, n (%) | 7 (6.5) |
* Six participants received both a calcineurin inhibitor (tacrolimus or ciclosporin) and an mTOR inhibitor.